Evaluation of photoreceptors health and function in diabetic retinopathy patients using a high-resolution retinal imaging device with controlled light stimulus

使用受控光刺激的高分辨率视网膜成像设备评估糖尿病视网膜病变患者的光感受器健康和功能

• 批准号: 10696696
• 负责人: Mircea Mujat
• 金额: $ 33.11万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10696696
• 关键词: Area; Biological Markers; Blindness; Blood flow; Brain; Clinical; Collaborations; Color; Communities; Computers; Cone; Development; Diabetes Mellitus; Diabetic Retinopathy; Diameter; Early Diagnosis; Evaluation; Eye diseases; Feedback; Frequencies; Functional Imaging; Functional disorder; Government; Health; Image; Imaging Device; Impairment; Individual; Investigation; Lasers; Learning; Length; Light; Lighting; Location; Measurement; Measures; Metabolic; Methods; Monitor; Ophthalmoscopy; Optical Coherence Tomography; Optics; Patients; Pattern; Performance; Persons; Phase; Photoreceptors; Quality of life; Research; Resolution; Retina; Retinal Cone; Retinal Diseases; Retinal Photoreceptors; Scanning; Signal Transduction; Site; Spottings; Stimulus; System; Techniques; Technology; Testing; Tissues; Validation; Vision; Visual; Volunteer Group; adaptive optics; adaptive optics scanning laser ophthalmoscopy; clinical effect; cohort; design; experience; imager; imaging platform; imaging system; in vivo; instrument; light effects; negative affect; neural; neurovascular coupling; next generation; novel therapeutics; physical science; programs; response; retina blood vessel structure; retinal imaging; tool; transmission process; volunteer

Project Summary/Abstract Physical Sciences Inc (PSI), in collaboration with Joslin Diabetes Center (JDC), proposes to enable objective characterization of the photoreceptor response to light and thus quantification of differences between normal and diseased eyes by adding controlled light stimulus capabilities to an existing high-resolution retinal imaging platform and validating it on a group of volunteers at JDC. We aim to demonstrate the ability to induce and measure vessel diameter changes and to induce and measure reflectivity, transmission, and length changes in cone photoreceptors with the purpose of developing robust biomarkers for diabetic retinopathy (DR). Functional testing of retinal circuitry can provide an unbiased evaluation of one’s vision and enable early detection of retinal diseases and monitoring treatment results. PSI has been developing and offering multiple types of commercial high-resolution retinal imagers for more than fifteen years and is well known as one of the leaders in the field. Based on this experience, we propose to develop and implement light flicker stimulus capabilities in our multichannel adaptive optics retinal imaging (MAORI-X5) platform to objectively test retinal function. MAORI-X5 combines AO-assisted optical coherence tomography (OCT) and scanning laser ophthalmoscopy (SLO) in one instrument and provides in vivo cellular-level resolution imaging of retinal microstuctures. There is no commercially available SLO or OCT system with light flicker capabilities. We propose to fill in this gap and enhance the capabilities of our retinal imaging platform by implementing two types of light flicker: local, cone-level illumination for testing the health and function of photoreceptors, and large area illumination for testing neurovascular coupling. Both types of measurements will reveal the effects of light stimulation with cellular-level resolution. Adding stimulus capabilities to MAORI-X5 enables investigations of neurovascular coupling and functional assessment of retinal photoreceptors on a commercially available platform. We will validate the ability of the technique to measure cellular level effects in Phase I as a proof-of-principle demonstration on a very limited cohort of ten volunteers in collaboration with our clinical partner, Dr. Jennifer Sun, at JDC. A more extensive study will be proposed to quantify these effects and demonstrate clinical usefulness in a subsequent Phase II. PSI prior experience developing advanced ophthalmic imaging systems gives us a competitive advantage in developing the proposed functionality. A successful completion of the Phase I and a subsequent Phase II development will provide clinicians with a high-performance retinal imaging platform for functional imaging. Early adaptors of this technology within the research community will grow our understanding of vision and its disruption by DR, and will enable the investigation of the effects of new drugs and therapies. PSI, the only company worldwide offering commercially AO-SLO-OCT instruments, proposes to develop the next generation of retinal imaging research instruments as a reliable tool to quantify clinically the effects of DR on vision.

项目摘要/摘要 物理科学公司（PSI），与乔斯林糖尿病中心（JDC）合作，提案启用 光感受器对光的反应的客观表征，从而在 通过在现有的高分辨率视网膜中添加受控的光刺激能力，通过添加受控的光刺激能力 成像平台并在JDC的一组志愿者身上验证它。我们旨在证明影响能力 并测量容器直径变化，并诱导和测量反射率，传播和长度 锥形感受器的变化，目的是为糖尿病性视网膜病变开发可靠的生物标志物 （DR）。视网膜电路的功能测试可以提供对自己视力的公正评估，并启用 早期发现残留疾病和监测治疗结果。 PSI一直在开发和提供多种类型的商业高分辨率残差图像。 超过15年，被称为该领域的领导人之一。根据这一经验，我们 在我们的多通道自适应光学元件中，开发和实施轻闪烁刺激功能的提案 成像（MAORI-X5）平台，以客观测试剩余功能。 Maori-X5结合了AO辅助光学 连贯断层扫描（OCT）和一种仪器中的扫描激光眼镜检查（SLO），并提供 视网膜微裂变的体内细胞水平分辨率成像。没有商业可用的SLO或 具有轻闪烁功能的OCT系统。我们建议填补这一空白并增强我们的能力 视网膜成像平台通过实施两种类型的轻闪烁：局部，锥体级照明用于测试 光感受器的健康和功能，以及用于测试神经血管耦合的大面积照明。两个都 测量的类型将揭示通过细胞水平分辨率的光刺激的影响。添加刺激 MAORI-X5的能力使神经血管耦合和功能评估的投资 市售平台上的视网膜感受器。我们将验证该技术的能力 测量I期的细胞水平效应作为原则证明，在非常有限的队列中 志愿者与JDC的临床合作伙伴Jennifer Sun博士合作。一项更广泛的研究将是 提议量化这些影响并在随后的II期中证明临床实用性。 PSI先前开发高级眼科成像系统的经验为我们带来了竞争优势 在开发提出的功能时。成功完成I阶段和随后的II期 开发将为临床医生提供功能成像的高性能视网膜成像平台。 研究社区中该技术的早期适配器将提高我们对愿景和 DR的破坏，并将能够投资新药和疗法的影响。 PSI，唯一的 公司在全球提供商业上的AO-SLO-OCT工具，并提出发展下一代的建议 视网膜成像研究工具是一种可靠的工具，可以在临床上量化DR对视力的影响。